Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset

Overview

Journal JACC Clin Electrophysiol

Specialty Cardiology & Vascular Diseases

Date 2018 May 16

PMID 29759870

Citations 15

Authors

Aatish Garg

Monica Khunger

Sinziana Seicean

Mina K Chung

Patrick J Tchou

Affiliations

Soon will be listed here.

Abstract

Objectives: This study sought to compare the risk of thromboembolism after cardioversion within 48 h of atrial fibrillation (AF) onset in patients therapeutically versus not therapeutically anticoagulated.

Background: Although guidelines do not mandate anticoagulation for cardioversion within 48 h of AF onset, risk of thromboembolism in this group has been understudied.

Methods: Patients undergoing cardioversion within 48 h after AF onset were identified from a prospectively collected database and retrospectively reviewed to determine anticoagulation status and major thromboembolic events within 30 days of cardioversion.

Results: Among 567 cardioversions in 484 patients without therapeutic anticoagulation (mean CHADS-VASc score, 2.3 ± 1.7), 6 had neurological events (1.06%), all in patients on aspirin alone. Among 898 cardioversions in 709 patients on therapeutic anticoagulation (mean CHADS-VASc score, 2.6 ± 1.7; p = 0.017), 2 neurological events occurred (0.22%; OR: 4.8; p = 0.03), both off anticoagulation at the time of stroke. No thromboembolic events occurred in patients with CHADS-VASc score <2 (p = 0.06) or in patients with postoperative AF.

Conclusions: In patients with acute-onset AF, odds of thromboembolic complications were almost 5 times higher in patients without therapeutic anticoagulation at the time of cardioversion. However, no events occurred in post-operative patients and in those with CHADS-VASc scores of <2, supporting the utility of accurate assessment of AF onset and risk stratification in determining the need for anticoagulation for cardioversion of AF <48 h in duration.

Citing Articles

Risk of stroke with reduced dose direct oral anticoagulants vs standard dose anticoagulation after cardioversion of atrial fibrillation: A systematic review and meta-analysis.

Quevillon T, Slade E, Michael F, Benz A, McIntyre W, Parkash R Heart Rhythm O2. 2025; 5(12):942-950.

PMID: 39803618 PMC: 11721732. DOI: 10.1016/j.hroo.2024.09.011.

Computed Tomography to Exclude Cardiac Thrombus in Atrial Fibrillation-An 11-Year Experience from an Academic Emergency Department.

Gupta S, Lutnik M, Cacioppo F, Lindmayr T, Schuetz N, Tumnitz E Diagnostics (Basel). 2024; 14(7).

PMID: 38611612 PMC: 11011443. DOI: 10.3390/diagnostics14070699.

The Optimal Management of Patients with Atrial Fibrillation and Acute Heart Failure in the Emergency Department.

Velliou M, Sanidas E, Diakantonis A, Ventoulis I, Parissis J, Polyzogopoulou E Medicina (Kaunas). 2023; 59(12).

PMID: 38138216 PMC: 10744575. DOI: 10.3390/medicina59122113.

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Joglar J, Chung M, Armbruster A, Benjamin E, Chyou J, Cronin E J Am Coll Cardiol. 2023; 83(1):109-279.

PMID: 38043043 PMC: 11104284. DOI: 10.1016/j.jacc.2023.08.017.

Joglar J, Chung M, Armbruster A, Benjamin E, Chyou J, Cronin E Circulation. 2023; 149(1):e1-e156.

PMID: 38033089 PMC: 11095842. DOI: 10.1161/CIR.0000000000001193.

References

Hansen M, Jepsen R, Olesen J, Ruwald M, Karasoy D, Gislason G . Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace. 2014; 17(1):18-23. DOI: 10.1093/europace/euu189. View

BJERKELUND C, Orning O . The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969; 23(2):208-16. DOI: 10.1016/0002-9149(69)90068-x. View

Weinberg D, Mancini J . Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol. 1989; 63(11):745-6. DOI: 10.1016/0002-9149(89)90264-6. View

Airaksinen K, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F . Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013; 62(13):1187-92. DOI: 10.1016/j.jacc.2013.04.089. View

Burton J, Vinson D, Drummond K, Strout T, Thode H, McInturff J . Electrical cardioversion of emergency department patients with atrial fibrillation. Ann Emerg Med. 2004; 44(1):20-30. DOI: 10.1016/j.annemergmed.2004.02.016. View

Berger M, Schweitzer P . Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1999; 82(12):1545-7, A8. DOI: 10.1016/s0002-9149(98)00704-8. View

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

Stoddard M, Dawkins P, Prince C, Ammash N . Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995; 25(2):452-9. DOI: 10.1016/0735-1097(94)00396-8. View

Vinson D, Hoehn T, Graber D, Williams T . Managing emergency department patients with recent-onset atrial fibrillation. J Emerg Med. 2010; 42(2):139-48. DOI: 10.1016/j.jemermed.2010.05.017. View

10.

LOWN B, Perlroth M, KAIDBEY S, Abe T, HARKEN D . "Cardioversion" of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients. N Engl J Med. 1963; 269:325-31. DOI: 10.1056/NEJM196308152690701. View

11.

Lin H, Wolf P, Beiser A, Kase C, Benjamin E, DAgostino R . Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996; 27(10):1760-4. DOI: 10.1161/01.str.27.10.1760. View

12.

Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D . Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke. 2013; 44(12):3357-64. DOI: 10.1161/STROKEAHA.113.001884. View

13.

Glotzer T, Daoud E, Wyse D, Singer D, Ezekowitz M, Hilker C . The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009; 2(5):474-80. DOI: 10.1161/CIRCEP.109.849638. View

14.

Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. DOI: 10.1056/NEJMoa1107039. View

15.

Klein A, Grimm R, Murray R, Apperson-Hansen C, Asinger R, Black I . Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001; 344(19):1411-20. DOI: 10.1056/NEJM200105103441901. View

16.

Stiell I, Clement C, Perry J, Vaillancourt C, Symington C, Dickinson G . Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter. CJEM. 2010; 12(3):181-91. DOI: 10.1017/s1481803500012227. View

17.

Jacoby J, Cesta M, Heller M, Salen P, Reed J . Synchronized emergency department cardioversion of atrial dysrhythmias saves time, money and resources. J Emerg Med. 2005; 28(1):27-30. DOI: 10.1016/j.jemermed.2004.07.011. View

18.

Weigner M, Caulfield T, Danias P, Silverman D, Manning W . Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997; 126(8):615-20. DOI: 10.7326/0003-4819-126-8-199704150-00005. View

19.

Scheuermeyer F, Grafstein E, Stenstrom R, Innes G, Poureslami I, Sighary M . Thirty-day outcomes of emergency department patients undergoing electrical cardioversion for atrial fibrillation or flutter. Acad Emerg Med. 2010; 17(4):408-15. DOI: 10.1111/j.1553-2712.2010.00697.x. View

20.

You J, Singer D, Howard P, Lane D, Eckman M, Fang M . Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e531S-e575S. PMC: 3278056. DOI: 10.1378/chest.11-2304. View